Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2018 - 2020)
Historic Long-Term Deferred Tax for Ionis Pharmaceuticals (IONS) over the last 5 years, with Q3 2020 value amounting to $307.7 million.
- Ionis Pharmaceuticals' Long-Term Deferred Tax rose 797.9% to $307.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $307.7 million, marking a year-over-year increase of 797.9%. This contributed to the annual value of $305.6 million for FY2019, which is 507.61% up from last year.
- Ionis Pharmaceuticals' Long-Term Deferred Tax amounted to $307.7 million in Q3 2020, which was up 797.9% from $306.0 million recorded in Q2 2020.
- Over the past 5 years, Ionis Pharmaceuticals' Long-Term Deferred Tax peaked at $309.6 million during Q1 2020, and registered a low of $276.4 million during Q2 2019.
- In the last 3 years, Ionis Pharmaceuticals' Long-Term Deferred Tax had a median value of $298.2 million in 2018 and averaged $294.8 million.
- In the last 5 years, Ionis Pharmaceuticals' Long-Term Deferred Tax soared by 507.61% in 2019 and then soared by 1167.44% in 2020.
- Ionis Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $290.8 million in 2018, then increased by 5.08% to $305.6 million in 2019, then grew by 0.71% to $307.7 million in 2020.
- Its Long-Term Deferred Tax was $307.7 million in Q3 2020, compared to $306.0 million in Q2 2020 and $309.6 million in Q1 2020.